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Objective. To estimate the incidence and preva-
lence of systemic lupus erythematosus (SLE) in a so-
ciodemographically diverse southeastern Michigan
source population of 2.4 million people.
Methods. SLE cases fulfilling the American Col-
lege of Rheumatology classification criteria (primary
case definition) or meeting rheumatologist-judged SLE
criteria (secondary definition) and residing in Wayne or
Washtenaw Counties during 2002–2004 were included.
Case finding was performed from 6 source types, includ-
ing hospitals and private specialists. Age-standardized
rates were computed, and capture–recapture was per-
formed to estimate underascertainment of cases.
Results. The overall age-adjusted incidence and
prevalence (ACR definition) per 100,000 persons were
5.5 (95% confidence interval [95% CI] 5.0–6.1) and 72.8
(95% CI 70.8–74.8). Among females, the incidence was
9.3 per 100,000 persons and the prevalence was 128.7
per 100,000 persons. Only 7 cases were estimated to
have been missed by capture–recapture, adjustment for
which did not materially affect the rates. SLE preva-
lence was 2.3-fold higher in black persons than in white
persons, and 10-fold higher in females than in males.
Among incident cases, the mean  SD age at diagnosis
was 39.3  16.6 years. Black SLE patients had a higher
proportion of renal disease and end-stage renal disease
(ESRD) (40.5% and 15.3%, respectively) as compared to
white SLE patients (18.8% and 4.5%, respectively).
Black patients with renal disease were diagnosed as
having SLE at younger age than white patients with
renal disease (mean  SD 34.4  14.9 years versus
41.9  21.3 years; P  0.05).
Conclusion. SLE prevalence was higher than has
been described in most other population-based studies
and reached 1 in 537 among black female persons.
There were substantial racial disparities in the burden
of SLE, with black patients experiencing earlier age at
diagnosis, >2-fold increases in SLE incidence and prev-
alence, and increased proportions of renal disease and
progression to ESRD as compared to white patients.
Estimating the incidence and prevalence of sys-
temic lupus erythematosus (SLE) in the general popu-
The findings and conclusions reported herein are those of the
authors and do not necessarily represent the official position of the US
Centers for Disease Control and Prevention, the Michigan Depart-
ment of Community Health, or the National Institutes of Health.
Supported by cooperative agreements between the CDC and
the Michigan Department of Community Health (U58/CCU522826
and U58/DP001441), the NIH (National Center for Research Re-
sources grant UL1-RR-024986), and the Herbert and Carol and
Amster Lupus Research Fund. Dr. Somers’ work was supported in part
by the NIH (grant K01-ES-019909). Dr. Marder’s work was supported
in part by the NIH (grant K12-HD-001438).
1Emily C. Somers, PhD, ScM, Wendy Marder, MD, MS,
Patricia Cagnoli, MD, Emily E. Lewis, BS, Lu Wang, PhD, Jeffrey J.
Wing, MPH, Diane Shaltis, BAS, W. Joseph McCune, MD: University
of Michigan, Ann Arbor; 2Peter DeGuire, MPH: Michigan Depart-
ment of Community Health, Lansing; 3Caroline Gordon, MD, FRCP:
University of Birmingham, Birmingham, UK; 4Charles G. Helmick,
MD: CDC, Atlanta, Georgia; 5J. Patricia Dhar, MD: Wayne State
University, Detroit, Michigan; 6James Leisen, MD: Henry Ford
Health System, Detroit, Michigan.
Address correspondence to Emily C. Somers, PhD, ScM,
University of Michigan, Division of Rheumatology, 24 Frank Lloyd
Wright Drive, PO Box 385, Ann Arbor, MI 48105. E-mail: emsomers@
umich.edu.
Submitted for publication May 3, 2013; accepted in revised
form October 15, 2013.
369
lation is challenging and resource-intensive to perform.
In part, this is due to the protean and systemic nature of
the disease and the attendant diagnostic complexity that
requires the synthesis of a multitude of clinical and
laboratory findings, often obtained from a variety of
health care settings. In the US, the fragmented health
care system and lack of existing infrastructure suitable
for the surveillance of autoimmune diseases such as SLE
further complicates the implementation of population-
based efforts to ascertain and validate cases. As a result,
existing estimates of the incidence and prevalence of
SLE vary widely, with close to 10-fold differences in
published incidence estimates from the US (1,2). In
response to the need for accurate and contemporary
statistics related to the risk and burden of SLE, we
developed the Michigan Lupus Epidemiology and Sur-
veillance (MILES) program, which covers a sociodemo-
graphically diverse population in southeastern Michigan,
consisting of 2.4 million persons or 25% of the
population of Michigan (3).
In partnership with the Centers for Disease Con-
trol and Prevention (CDC) and the Michigan Depart-
ment of Community Health (MDCH), we implemented
the MILES program with the primary goal of ascertain-
ing and validating all diagnosed cases of SLE in persons
residing in the geographic region of the source popula-
tion, in order to derive population-based incidence and
prevalence estimates for SLE during 2002–2004. Given
the large scope and diversity of the underlying popula-
tion, the MILES program has enabled the characteriza-
tion of disease patterns in population subsets with a high
level of detail and precision.
PATIENTS AND METHODS
Regultory approvals. As described elsewhere (4), this
lupus surveillance project was conducted under a grant of au-
thority from the MDCH as a public health surveillance activity,
with Institutional Review Board exemptions and waiver for
informed consent from the CDC, the MDCH, and the Uni-
versity of Michigan (UM).
Source population, catchment area, and surveillance
period. The source population consisted of 2.4 million resi-
dents of the counties of Wayne (includes Detroit) and Wash-
tenaw (includes Ann Arbor) in southeastern Michigan, com-
prising a mixed urban/rural population (57.7% white, 38.7%
black, 3.7% other racial/ethnic groups according to 2003 US
Census estimates) (3). Location of “usual residence” was
determined according to the 2000 Census rules (5). To capture
SLE cases receiving health care outside their residential
county, the catchment area for case ascertainment also in-
cluded neighboring Oakland County, as determined by a pilot
analysis of data on health care utilization patterns (6). The
surveillance period encompassed January 1, 2002 through
December 31, 2004.
SLE definitions and verification of diagnosis. Primary
analyses were based on classification of SLE according to
fulfillment of the current research standard: 4 of 11 Ameri-
can College of Rheumatology (ACR) criteria for SLE (7,8)
(or, ACR definition). Secondary analyses used our rheumatol-
ogist definition, which was based on the consensus judgment of
our team of 6 board-certified rheumatologist-investigators
representing the major academic medical centers in southeast-
ern Michigan. As detailed further in the data collection sec-
tion below, in addition to data elements comprising the ACR
classification criteria, we systematically ascertained data ele-
ments from other case definitions, including the Boston
weighted criteria (9), as well as from validated SLE activity
measures and components of the new Systemic Lupus Inter-
national Collaborating Clinics (SLICC) criteria for the classi-
fication of SLE (10). In addition, free-text note fields were
available for each organ system and included data on con-
founding diagnoses or other salient points substantiating the
record. Thus, the judgment of the rheumatologists was based
on the synthesis of medical history details beyond the ACR or
other classification criteria. Based on the rheumatologist def-
inition, some patients who satisfied fewer than 4 ACR criteria
and had biopsy-proven lupus nephritis and/or additional ob-
jective features of SLE were considered to have SLE. The
rheumatologist definition also excluded some patients who
satisfied 4 ACR criteria but who had met subcriteria that
could more likely be attributed to a comorbid illness, such as
hepatitis C virus infection. If there was disagreement between
the ACR and rheumatologist classifications, the record was
reviewed independently by at least 2 physician-investigators to
assure consensus on the rheumatologist definition that was
recorded.
Case ascertainment. Multiple case-finding sources
were used, including hospitals/health systems, private practice
specialists (rheumatologists, nephrologists, and dermatolo-
gists), Medicaid claims, the US Renal Data System for end-
stage renal disease (ESRD) patients with a diagnosis of SLE,
and commercial laboratories. In addition, a random sample of
primary care practices was taken in order to explore the utility
of primary care practices for case finding, though this source
did not yield adequate data for analysis. Case finding was
customized to be compatible and as comprehensive as possible
for each source/facility; queries were based on International
Classification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) codes, Systematized Nomenclature of Med-
icine (SNOMED) codes for pathology reports, keyword/text
searching of medical records, and/or other patient logs, as
applicable (codes and keywords are listed in Supplementary
Table 1, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38238/abstract).
Case ascertainment and abstraction in the source
population was completed at 27 of 28 hospitals (96.4%), 59 of
67 rheumatologists (88.1%), 74 of 84 nephrologists (88.1%),
and 50 of 86 dermatologists (58.1%). Of the 18 rheumatolo-
gists and nephrologists that were not included, 20% had
retired/closed practices since the surveillance period, 39%
declined to participate, and the remainder were affiliated with
larger health systems that we accessed. Of the dermatologists
who were not included, the majority were not directly relevant
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to our surveillance program because of their area of subspe-
cialization (e.g., cosmetic dermatology or Mohs surgery). In
neighboring Oakland County, case ascertainment and abstrac-
tion were completed at an additional 10 hospitals and 20
private practices.
Data collection. Detailed sociodemographic and clini-
cal data were collected (see Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38238/abstract). Relevant
clinical data included the ACR (7,8) and SLICC (10) classi-
fication criteria for SLE, components of validated SLE disease
activity instruments (e.g., the SLE Disease Activity Index
[SLEDAI] [11], the British Isles Lupus Assessment Group
Index [BILAG] [12], and the Systemic Lupus Activity Measure
[SLAM] [13,14]), and ACR consensus definitions (neuropsy-
chiatric lupus) (15). Data elements were selected based on an
iterative process among a working group of 10 rheumatology/
public health faculty members. Clinical data included dates
of SLE diagnosis and, for the major features of SLE (e.g., ACR
criteria), both the date of onset and the source of the data
(physician observation, medical document, or patient report),
potentially confounding diagnoses (e.g., hepatitis C virus in-
fection), common SLE medications, and the diagnosis re-
corded in the patient’s medical chart. For some data elements
(e.g., antiphospholipid antibodies), the results of multiple
assessments were recorded.
Data were collected by abstractors who had completed
standardized, rigorous training, which included completion
of pilot abstractions that were reviewed in detail by the
rheumatologist-investigators against the source documenta-
tion. Continual quality assurance of data abstraction included
reabstraction of 5% of the records, as well as physician review
of all abstractions and provision of feedback. For each poten-
tial case, abstractors manually reviewed all available records. A
medical record search engine (the Universal Medical Record
Search Engine [UMERSE]) (16) was used when available to
screen electronic records for keywords. Data were entered into
a secure electronic data-capture system. Completed abstrac-
tions, representing the synthesis of data from all available
sources, were reviewed in detail by at least one rheumatologist-
investigator, who requested further information if necessary.
Statistical analysis. All cases contributed person-years
to the prevalence numerators for each year (from diagnosis
onward) of residence in the source population during 2002–
2004 and to the incidence numerators for the year of diagnosis
(if during 2002–2004). Age-, sex-, and race-specific denomina-
tors for 2002–2004, by county in Michigan, were based on US
Census data (the vintage 2009 bridged-race population files
Figure 1. Flow diagram of the ascertainment and verification of cases of systemic lupus erythematosus (SLE) in the Michigan Lupus Epidemiology
and Surveillance program. For the category of not incident (inc) or prevalent (prev) during surveillance period, the prevalent cases included both
newly diagnosed (incident) and existing cases (i.e., the incident cases are a subset of the prevalent cases). Dx  diagnosis; ACR  American College
of Rheumatology; Rheum  rheumatologist.
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produced by the National Center for Health Statistics and the
US Census Bureau) (3,17). The race-bridging methodology is
used to create comparability between multiple-race (31 race
categories) and single-race (4 race categories) data collection
systems (1). Crude and stratum-specific mean annual incidence
and prevalence rates were computed per 100,000 person-years.
Rates were estimated as the number of incident or prevalent
cases divided by the relevant number of person-years, and
exact 95% confidence intervals (95% CIs) were computed.
Age-standardized rates were calculated using the direct
method (using 5-year age bands), with weights based on the
2000 US Standard Population (18).
To estimate underascertainment of cases, capture–
recapture analysis (19) was used to take account for the degree
of overlap among multiple case-finding sources. Specifically,
we fit log-linear models (20) assuming there was no “3-way”
interaction of sources. Contingency tables were set up with
count data for the number of cases uniquely identified for each
source and for pairs of sources. Each of these cells represented
a potential predictor in the models, which included each of the
sources and interaction terms, and then nonsignificant inter-
actions were removed from the final model (up to 9 pairs of
2-way interactions for the 5-source models, and up to 5 pairs of
2-way interactions for the 4-source models). Goodness-of-fit
statistics were used to identify the best models based on
Pearson’s chi-square and the Bayesian information criterion
(BIC) (21,22). The BIC includes 2 terms, the first corresponds
to how well the data fit the model, and the second is a penalty
for the model complexity. Thus, the BIC reflects the trade-off
between model complexity and goodness-of-fit. Analyses were
performed using SAS 9.2 (SAS Institute), R (R Foundation),
and Stata (StataCorp) software packages.
RESULTS
Characteristics of the study population. As de-
picted by the flow diagram in Figure 1, among the 13,170
potential cases screened, a total of 2,278 prevalent cases,
with a subset of 426 incident cases, were confirmed as
meeting eligibility criteria (residency and time period)
Table 1. Crude and age-standardized mean annual incidence and prevalence rates (per 100,000) of SLE in southeastern Michigan, 2002–2004,
according to the ACR and rheumatologist case definitions, categorized by race/ethnicity and sex*
Race/ethnicity,
sex














Overall† 399 5.6 (5.0–6.2) 5.5 (5.0–6.1) 343 4.8 (4.3–5.3) 4.7 (4.3–5.3)
Male 54 1.6 (1.2–2.0) 1.5 (1.1–2.0) 50 1.4 (1.1–1.9) 1.4 (1.0–1.9)
Female 345 9.3 (8.4–10.4) 9.3 (8.3–10.3) 293 8.0 (7.1–8.9) 7.9 (7.0–8.9)
Black 215 7.9 (6.9–9.0) 7.9 (6.9–9.1) 204 7.5 (6.5–8.5) 7.5 (6.5–8.5)
Male 25 1.9 (1.2–2.8) 2.1 (1.3–3.0) 26 2.1 (1.3–3.0) 2.1 (1.3–3.0)
Female 190 12.8 (11.1–14.8) 12.8 (11.1–14.8) 178 12.1 (10.4–14.0) 12.0 (10.3–13.9)
White 157 3.8 (3.2–4.4) 3.7 (3.1–4.3) 115 2.8 (2.3–3.3) 2.7 (2.2–3.3)
Male 24 1.2 (0.7–1.7) 1.2 (0.7–1.7) 19 0.9 (0.6–1.4) 0.9 (0.6–1.4)
Female 133 6.3 (5.3–7.5) 6.3 (5.2–7.4) 96 4.6 (3.7–5.6) 4.5 (3.7–5.5)
Prevalence
Overall† 2,139 72.1 (70.1–74.1) 72.8 (70.8–74.8) 1,909 64.1 (62.3–66.0) 64.6 (62.8–66.5)
Male 182 12.4 (11.3–13.7) 12.8 (11.7–14.1) 177 12.2 (11.1–13.4) 12.5 (11.4–13.8)
Female 1,957 127.8 (124.2–131.5) 128.7 (125.1–132.4) 1,732 112.7 (109.3–116.2) 113.4 (110.0–116.9)
Black 1,219 105.8 (102.0–109.8) 111.6 (107.7–115.6) 1,142 98.2 (94.5–102.0) 103.0 (99.2–106.9)
Male 93 17.8 (15.5–20.2) 19.3 (17.0–21.9) 96 18.3 (16.0–20.8) 19.9 (17.6–22.6)
Female 1,126 181.6 (174.8–188.7) 186.3 (179.4–193.4) 1,046 167.0 (160.4–173.7) 170.5 (164.0–177.4)
White 820 48.7 (46.6–50.9) 47.5 (45.5–49.7) 679 40.8 (38.9–42.8) 39.8 (37.9–41.7)
Male 76 8.8 (7.5–10.1) 8.7 (7.5–10.1) 612 7.9 (6.7–9.2) 7.8 (6.6–9.1)
Female 744 88.0 (84.0–92.1) 86.7 (82.8–90.8) 67 73.2 (69.6–76.9) 72.1 (68.5–75.9)
Asian/PI 25 27.1 (20.7–34.9) 24.9 (18.7–32.4) 21 22.2 (16.4–29.3) 20.8 (15.2–27.7)
Male 3 5.3 (2.0–11.6) 4.4 (1.4–10.4) 3 5.3 (2.0–11.6) 4.3 (1.4–10.4)
Female 22 49.6 (37.3–64.9) 45.0 (33.3–59.5) 18 39.5 (28.6–53.2) 36.9 (26.3–50.1)
Hispanic‡ 39 33.6 (27.3–40.9) 42.1 (35.0–50.2) 36 31.9 (25.8–39.0) 40.1 (33.1–47.9)
Male 7 11.5 (6.8–18.2) 14.9 (9.3–22.1) 7 11.5 (6.8–18.2) 14.9 (9.3–22.1)
Female 32 58.4 (46.3–72.5) 71.4 (58.0–86.8) 29 54.8 (43.1–68.5) 67.6 (54.7–82.9)
* Rates are per 100,000 persons. SLE  systemic lupus erythematosus; 95% CI  95% confidence interval.
† Represents the entire population, including persons whose race/ethnicity was not known. The numerator for this category is larger than the sum
of the individual subsets, since it includes persons of other racial/ethnic classifications. Incidence estimates according to the American College of
Rheumatology (ACR) definition are not presented for other racial/ethnic groups because of the small numbers: 7 Asian/Pacific Islander (PI), 1
American Indian/Alaska Native, and 9 Hispanic patients. For the 19 patients of unknown race, there were 8 incident cases according to the ACR
definition; rates were not calculated for this subset since the appropriate population denominator could not be determined. For prevalent cases
according to the ACR definition, 3 were American Indian/Alaska Natives and 72 were of unknown race.
‡ Hispanic/Latino ethnicity is recorded separately from race; therefore, persons in this ethnicity category are also represented in the race categories.
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and either the ACR or the rheumatologist definitions of
SLE. A larger number of cases fulfilled the ACR
definition as compared to the rheumatologist definition
(2,139 versus 1,909) (Figure 1). The demographic fea-
tures of the cases meeting the ACR definition were as
follows: 1,957 (91.5%) female; 1,219 (57.0%) black, 820
(38.3%) white, 100 (4.7%) other/unknown race (Table
1). The vast majority of cases (2,124 of 2,278 [93.2%])
that were included in the Registry were ascertained by
just 4 of the 6 case-finding source categories (Figure 2).
Incidence rates. According to the ACR defini-
tion, 399 cases were newly diagnosed during 2002–2004
(average of 133 new cases annually). Crude and age-
standardized rates according to both SLE definitions,
stratified by sex and race, are detailed in Table 1 and
Figure 3A. By the ACR definition, the age-standardized
incidence rates were as follows: for the overall popula-
tion, 5.5 per 100,000 person-years (95% CI 5.0–6.1); for
the female population, 9.3 (95% CI 8.3–10.3); and for
the male population, 1.5 (95% CI 1.1–2.0) (incidence
ratio of females to males 6:1). The age-standard-
ized incidence rate among black patients was 7.9 (95%
CI 6.9–9.1) and among white patients was 3.7 (95% CI
3.1–4.3). The incidence for black females (12.8 [95% CI
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Figure 3. A and B, Forest plots of the age-standardized incidence (A)
and prevalence (B) rates of systemic lupus erythematosus (SLE),
according to the American College of Rheumatology (ACR) and
rheumatologist (Rheum) case definitions, categorized by sex and
race/ethnicity. Values are the point estimates with 95% confidence
intervals (95% CIs). Vertical dotted lines indicate the point estimates
for the overall male and female rates according to the ACR definition.
Numbers shown on the right y-axis are the average annual number of
SLE cases during 2002–2004, with the age-standardized rate (ASR)
per 100,000 persons and 95% CI. Pacif  Pacific.
Figure 2. Venn diagram depicting the overlap of cases identified by
the 4 categories of case-finding sources used in the primary capture–
recapture models. This diagram corresponds to unique prevalent cases
classified as systemic lupus erythematosus (SLE) according to the
American College of Rheumatology (ACR) definition. Capture–
recapture modeling was performed using both 4-source and 5-source
models; the models that used the 4 case-finding sources presented in
this Venn diagram were determined to fit the data best and, thus,
represent our primary capture–recapture modeling. The majority of
cases in the registry (2,124 of 2,278 [93.2%]) meeting the ACR or
rheumatologist definitions were ascertained from these 4 case-finding
source categories. (The 2 case-finding sources that were not retained in
the primary models were Medicaid and laboratory.) Based on the
capture–recapture analysis of prevalent SLE cases meeting the ACR
criteria, we estimated that an additional 7 prevalent SLE cases were in
the source population (Wayne and Washtenaw Counties, Michigan,
2002–2004) but were not ascertained in the Registry. ESRD 
end-stage renal disease (data from US Renal Data System).
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CI 5.2–7.4]). Incidence rates were higher among black
male patients as compared to white male patients,
although they did not reach statistical significance (likely
due to the small number of male patients). The numbers
of incident cases for other racial/ethnic groups (7 Asian/
Pacific Islander, 1 American Indian/Alaska Native, and 9
Hispanic patients) were small; thus, the incidence rates
for these groups are not presented due to statistical
imprecision. Incidence patterns by race and sex were
similar according to the secondary rheumatologist defi-
nition, although the rates were slightly lower.
Capture–recapture modeling (applied to the
ACR definition) using 4- and 5-source models was
performed to assess the extent of underascertainment of
cases by our surveillance program. Based on goodness-
of-fit statistics, our primary capture–recapture models
incorporated the following 4 case-finding sources: hos-
pitals, rheumatology practices, nephrology/dermatology
practices, and US Renal Data System/ESRD database.
From this 4-source model, we estimated that we were
unable to identify 2 (95% CI 1–4) incident SLE cases in
the source population. Adjustment for this low level of
underascertainment did not materially affect the inci-
dence rates.
The mean  SD age at diagnosis in the ACR-
defined incident cases was 39.3  16.6 years and was
significantly younger in black female patients (37.1 
14.5 years) as compared to white female patients (43.9 
16.9 years; P  0.001), but was similar in black male
patients (36.4  18.6 years) as compared to white male
patients (41.0  19.9 years). Age-specific incidence rates
(Figure 4A) in black female patients rose from early
childhood and peaked in the twenties, while the rates for
white female patients increased more gradually and
plateaued from the thirties through fifties. Among
males, the incidence rates appeared more constant
across age groups.
Prevalence rates. From a total of 2,139 ACR-
defined prevalent cases, the annual average number of
person-years contributed during 2002–2004 was 1,708.
The prevalence rates, including sex- and race-specific
rates for both case definitions, are detailed in Table 1
and Figure 3B. The age-standardized prevalence was
72.8 per 100,000 person-years (95% CI 70.8–74.8) over-
all, 128.7 (95% CI 125.1–132.4) for females, and 12.8
(95% CI 11.7–14.1) for males. The age-standardized
prevalence among black persons was more than double
that for white persons, including among black females
(186.3 [95% CI 179.4–193.4]) as compared to white
females (86.7 [95% CI 82.8–90.8]). The estimated prev-
alence rates for Asians/Pacific Islander and Hispanic
persons were lower than for black persons, although the
small number of cases in these groups limits further
comparisons.
While the age-specific prevalence for both black
and white females peaked in the fourth decade of life,
from ages 10–69 years, black females had a significantly
higher prevalence than did white females or males of
either racial/ethnic group (Figure 4B), demonstrating
that the disproportionate disease burden among black
females pertained across the majority of the lifespan.
Based on our primary 4-source capture–recapture ana-
lyses (described above), we estimated that 7 (95% CI
5–10) prevalent SLE cases in the source population were
Figure 4. A and B, Age-specific average annual incidence (A) and
prevalence (B) rates (per 100,000 persons) of systemic lupus erythem-
atosus, according to the American College of Rheumatology (ACR)
case definitions, categorized by sex and race/ethnicity, in southeastern
Michigan, 2002–2004. Values are the point estimates; shading in A and
bars in B represent 95% confidence intervals.
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missed. Adjustment for this low level of underascertain-
ment did not materially affect the prevalence rates.
Clinical characteristics. The proportion of pa-
tients with prevalent SLE who satisfied each of the 11
individual ACR criteria was similar in patients identified
by either definition of SLE, but the rheumatologist
definition included a larger number of patients with
ESRD (Table 2). Black patients had a higher proportion
of renal involvement (2.2-fold) and ESRD (3.4-fold) as
compared to white patients. In the subset of ACR-
defined incident cases with renal disease, the mean 
SD age at SLE diagnosis was younger among black
patients (34.4  14.9 years) as compared to white
patients (41.9  21.3 years; P  0.05).
DISCUSSION
Epidemiologic data are fundamental to our un-
derstanding of the risk and burden of disease in the
population. However, such data are challenging and
resource intensive to derive in a fragmented health care
system and for diseases such as SLE, in which a hetero-
geneous constellation of clinical and laboratory features
is necessary to establish a diagnosis. Surveillance outside
of the tertiary care setting is imperative for capturing the
full spectrum of SLE, in order to identify cases receiving
health care in other settings. In the sociodemographi-
cally diverse MILES source population of 2.4 million,
there were, on average, 133 new cases and 1,708 preva-
lent cases of SLE annually during 2002–2004, yielding
age-standardized incidence and prevalence estimates
per 100,000 persons of 5.5 and 72.8, respectively. Using
more complete case-finding sources, we were able to
quantify at a new level of statistical precision the higher
risk and burden of SLE among women and minorities in
the general population of the US.
The majority of previously available data on the
epidemiology of SLE were derived from predominantly
homogeneous populations of European descent. As
reviewed elsewhere (23), previous North American and
European estimates of the prevalence of SLE in recent
years (1995–2008) have varied widely (from 32 to 150
per 100,000 persons) (23). Weighted mean estimates for
SLE based on studies published over the 3 earlier
decades (for the years 1965–1995) were 7.3 for the
incidence and 23.8 for the prevalence (24). Though
caution should be exercised when comparing results
between studies that may be heterogeneous in terms of
methodologies and population structures, in relation to
the weighted data, our rates in Michigan appear to be
similar for SLE incidence, though 3-fold higher for SLE
prevalence. The larger prevalence-to-incidence ratio in
our population, coupled with the higher prevalence
range in the more recent review, suggests that preva-
lence may be increasing, in part due to improved sur-
vival, over the last 2 decades. The net migration in
Michigan (i.e., the balance of in- and out-migration)
from 1985 through the end of the surveillance period
was relatively stable, including that among young adults
Table 2. Clinical manifestations among the prevalent cases of SLE, according to the ACR and rheumatologist case definitions*
Clinical manifestation



















Malar rash 1,055 (49.3) 520 (42.7) 483 (58.9)† 923 (48.4) 482 (42.2) 397 (58.5)†
Discoid rash 520 (24.3) 392 (32.2)† 111 (13.5) 456 (23.9) 350 (30.7)† 93 (13.7)
Photosensitivity 1,036 (48.4) 505 (41.4) 483 (58.9)† 850 (44.5) 442 (38.7) 370 (54.5)†
Oral ulcers 892 (41.7) 462 (37.9) 395 (48.2)† 726 (38.0) 405 (35.5) 295 (43.5)†
Arthritis 1,514 (70.8) 875 (71.8) 570 (69.5) 1,314 (68.8) 793 (69.4) 461 (67.9)
Serositis 938 (43.9) 559 (45.9) 347 (42.3) 837 (43.8) 522 (45.7) 288 (42.4)
Renal disorder 682 (31.9) 494 (40.5)† 154 (18.8) 671 (35.2) 495 (43.4)† 145 (21.4)
ESRD 231 (10.8) 187 (15.3)† 37 (4.5) 254 (13.3) 204 (17.9)† 42 (6.2)
Neurologic disorder 394 (18.4) 265 (21.7)† 115 (14.0) 354 (18.5) 243 (21.3)† 99 (14.6)
Hematologic disorder 1,411 (66.0) 814 (66.8) 529 (64.5) 1,247 (65.3) 737 (64.5) 453 (66.7)
Immunologic disorder 1,436 (67.1) 864 (71.0)† 503 (61.3) 1,372 (71.9) 841 (73.6)† 462 (68.0)
Antinuclear antibody 2,012 (94.1) 1,172 (96.1)† 750 (91.5) 1,818 (95.2) 1,102 (96.5)† 635 (93.5)
* Prevalent cases consisted of both new (incident) and existing cases of systemic lupus erythematosus (SLE) during the years 2002–2004. Clinical
manifestations consisted of the 11 American College of Rheumatology (ACR) criteria for SLE plus end-stage renal disease (ESRD). The overall
group represents the entire population, including persons whose race/ethnicity was not known. The numerator for this category is larger than the
sum of the individual subsets, since it includes persons of other racial/ethnic classifications.
† Significantly higher proportion of cases with the clinical manifestation between the black and white subgroups.
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(a reasonable proxy for a “healthy” population subset).
Thus, it does not appear that the premise for improved
survival was an artifact of migration patterns (25).
However, the possibility that persons with preexisting
lupus migrated into the source population in order to be
more proximate to medical care cannot be excluded.
We found a female-to-male incidence ratio of
6.2:1 and a female-to-male prevalence ratio of 10.1:1;
hence, males accounted for a higher proportion of newly
diagnosed cases as compared to existing cases in the
overall population, a pattern that pertained to both
black patients and white patients. Studies examining
race have documented higher rates in persons of African
descent: a study from Allegheny County, PA (for the
years 1985–1990) found an 3-fold incidence of SLE
among black females versus white females (9.2 versus
3.5 per 100,000 persons) (1); another study of the adult
population in Birmingham, UK (for 1992) found the
prevalence among African-Caribbeans to be 206 per
100,000 persons, as compared with 27.7 per 100,000
persons overall (26). In our population, black persons
had the highest risk and burden of SLE, with a 2.1-fold
higher incidence and a 2.3-fold higher prevalence (1 in
537 black females) than white persons, ratios somewhat
smaller than those reported elsewhere. The ability to
compare disease patterns in other racial and ethnic
groups is limited by the small numbers of these minor-
ities in our geographic region, though our data suggest
that black persons have a higher prevalence of SLE than
Asian/Pacific Islander or Hispanic persons.
As shown by the age-specific incidence rates, SLE
began earlier in the reproductive years in black females.
In late childhood, there was already a trend for black
girls to have an increased incidence compared to white
girls, and in the 20–50-year range, there was an early
incidence peak in black women, as compared to statis-
tically lower levels that plateaued among white women.
However, after the average age of menopause (51
years of age in the US) (27), the incidence rates in black
versus white women did not differ significantly. In
contrast to recent European studies describing a peak
incidence among females around the age of menopause
(28,29), the observation of peak incidence in this Mich-
igan population during the reproductive years is driven
by the early onset in black females. Higher genetic load
(number of SLE-susceptibility risk alleles) has been
associated with earlier disease onset among African
American, but not European American, SLE patients
(30), and gene–environment interactions may further
underlie observed racial differences in the natural his-
tory of this disease.
This study has several limitations. First, it was
based on review of medical records, rather than direct
patient examination, as most population-based epidemi-
ologic studies must. Second, race and ethnicity were
ascertained from records, not self-reports, which would
be the gold standard. Misclassification may be a partic-
ular concern for persons of Hispanic/Latino ethnicity,
since many medical records systems do not assess His-
panic ethnicity as a separate variable from race, which in
theory, could lead to underestimation. Third, although
we tried to reach all targeted health care sources, a few
(see the case ascertainment section above) did not
permit access, and the slow cooperation of others neces-
sitated active record reviews through 2011, requiring
increased allocation of resources in order to complete
the planned surveillance activities. The nonparticipating
sites did not appear to differ systematically from the
participating sites in terms of the demographics of the
populations served or other discernible features. Fourth,
we have likely underestimated incident and prevalent
cases, as there may be undiagnosed cases in the commu-
nity that have not reached the health care system for
screening and diagnosis, and other cases may have
received care outside the catchment area. However, the
capture–recapture analyses estimated that our surveil-
lance program missed only 7 cases in the source popu-
lation, pointing to highly effective methods of defining
catchment areas (based on a pilot analysis of health care
utilization patterns) and case ascertainment. Fifth, we
were unable to enlist the systematic cooperation of
primary care providers for even more comprehensive
findings, but the interactions we did have suggested that
primary care practices are likely to refer SLE patients
and are therefore unlikely to represent a large source of
additional cases.
This study also has several strengths. First, it
included multiple case-finding sources, including health
care facilities in a county contiguous to the source
population, which helped to ensure complete ascertain-
ment in a mobile population. Other researchers have
previously noted a substantial lack of overlap between
administrative case-finding sources, particularly for
prevalent SLE cases (31). Second, for each patient, there
was comprehensive abstraction and synthesis of detailed
clinical and laboratory data from multiple sources. With
the public health authority from the MDCH enabling
our access to all relevant records, a thorough profile
could be constructed for the majority of patients. In
some cases, the diagnosis of lupus could be confirmed
only after combining data from several hospitals or
physicians. Third, as noted above, the use of 2 analytical
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case definitions (ACR and rheumatologist definitions)
independently confirmed the diagnoses in the majority
of patients and accommodated the clinical uncertainty
of classifying SLE. The rheumatologist rates may be
considered to yield conservative estimates and, thus,
serve as a validated “lower bound” for the estimation of
SLE. Fourth, the collaboration with colleagues from the
CDC, the Georgia Lupus Registry, and the respective
state health departments for the methods and infrastruc-
ture development can serve as a prototype for the
implementation of other SLE registries, which will en-
hance opportunities for comparison of SLE statistics
across sites. Indeed, new registries based on this frame-
work have been initiated in regions with greater repre-
sentation of other minority groups (Asian/Pacific Is-
lander, Hispanic/Latino, and American Indian/Alaska
Native groups).
Based on this comprehensive, population-based
surveillance program, our data underscore substantial
levels of confirmed SLE cases and considerable racial
disparities in the epidemiology of SLE. Black persons
had the highest risk and burden of SLE, the earliest age
at diagnosis, and an increased proportion of renal
disease and progression to ESRD. Such data support a
focus of medical resources on early diagnosis and im-
proved treatment of lupus nephritis in young black
Americans.
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